



FILE COPY

October 4, 2005

Robert W. Pollock
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, New York 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to declare that the drug products Efavirenz Tablets for Oral Suspension 50 mg, 100 mg and 200 mg are suitable for submission in an abbreviated new drug application (ANDA), was received by this office on 10/04/2005. It was assigned docket number 2005P-0407/CP1 and it was filed on 10/04/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,


Gloria Ortega, Deputy Director
Division of Dockets Management
Office of Management Programs
Office of Management

2005P-0407

ACK 1